438 related articles for article (PubMed ID: 28838713)
1. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
Funazo T; Nomizo T; Kim YH
J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
[No Abstract] [Full Text] [Related]
2. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
[No Abstract] [Full Text] [Related]
3. Nivolumab improves survival for patients with advanced lung cancer.
Printz C
Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
[No Abstract] [Full Text] [Related]
4. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
Takeda T; Takeuchi M; Saitoh M; Takeda S
Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
[TBL] [Abstract][Full Text] [Related]
5. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
Komatsu T; Nakamura K; Kawase A
J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
[No Abstract] [Full Text] [Related]
6. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
[TBL] [Abstract][Full Text] [Related]
7. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.
Kimura H; Araya T; Yoneda T; Shirasaki H; Kurokawa K; Sakai T; Koba H; Tambo Y; Nishikawa S; Sone T; Kasahara K
Cancer Commun (Lond); 2019 Nov; 39(1):78. PubMed ID: 31753015
[No Abstract] [Full Text] [Related]
9. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
[TBL] [Abstract][Full Text] [Related]
10. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study.
Zhang G; Cheng R; Wang H; Zhang Y; Yan X; Li P; Zhang M; Zhang X; Yang J; Niu Y; Ma Z
Cancer Immunol Immunother; 2020 Mar; 69(3):399-405. PubMed ID: 31907567
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
Hida T
Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
[TBL] [Abstract][Full Text] [Related]
14. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab.
Scott SC; Pennell NA
J Thorac Oncol; 2018 Nov; 13(11):1771-1775. PubMed ID: 29935305
[TBL] [Abstract][Full Text] [Related]
15. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.
Park W; Kwon D; Saravia D; Desai A; Vargas F; El Dinali M; Warsch J; Elias R; Chae YK; Kim DW; Warsch S; Ishkanian A; Ikpeazu C; Mudad R; Lopes G; Jahanzeb M
Clin Lung Cancer; 2018 May; 19(3):280-288.e4. PubMed ID: 29336998
[TBL] [Abstract][Full Text] [Related]
16. Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions.
Tobita S; Kinehara Y; Tamura Y; Kurebe H; Ninomiya R; Utsu Y; Kohmo S; Sato B; Nagai K; Maruoka S; Jokoji R; Koyama S; Tachibana I
Thorac Cancer; 2020 Aug; 11(8):2357-2360. PubMed ID: 32567218
[TBL] [Abstract][Full Text] [Related]
17. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
18. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
Khunger M; Velcheti V
J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
[No Abstract] [Full Text] [Related]
19. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
Kobayashi K; Nakachi I; Naoki K; Satomi R; Nakamura M; Inoue T; Tateno H; Sakamaki F; Sayama K; Terashima T; Koh H; Abe T; Nishino M; Arai D; Yasuda H; Kawada I; Soejima K; Betsuyaku T;
Clin Lung Cancer; 2018 May; 19(3):e349-e358. PubMed ID: 29398578
[TBL] [Abstract][Full Text] [Related]
20. Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer.
Umehara K; Yama K; Goto K; Wakamoto A; Hatsuyama T; Honjo O; Saikai T; Fujita A; Sato H
Cancer Control; 2021; 28():1073274820985790. PubMed ID: 33733906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
